![Samuel Reich](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Samuel Reich
Directeur Général chez
SAB BIOTHERAPEUTICS, INC.
Fortune : 78 840 $ au 31/05/2026
Profil
Samuel J.
Reich was the founder of Acuity Pharmaceuticals, Inc., founded in 2002, where the title held was Vice President-Research & Development from 2002 to 2007.
Mr. Reich is the founder of Biscayne Pharmaceuticals, Inc., founded in 2011, holding the title of President & Director.
Mr. Reich is the founder of Biscayne Neurotherapeutics, Inc., founded in 2011, with the title of Executive Chairman & President from 2011 to 2018.
Current jobs include Chief Executive Officer & Director at SAB Biotherapeutics, Inc. starting in 2021, and Executive Chairman at SAB Sciences, Inc. Former jobs include Director, Chief Executive & Financial Officer at Big Cypress Acquisition Corp.
from 2020 to 2021, Executive Vice President at eXegenics, Inc. in 2007, and Executive Vice President-Ophthalmologics at OPKO Health, Inc. from 2007 to 2008.
Education includes undergraduate studies at Clark University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 02/03/2026 | 21 900 ( 0,05 % ) | 78 840 $ | 31/05/2026 |
Postes actifs de Samuel Reich
| Sociétés | Poste | Début |
|---|---|---|
| SAB BIOTHERAPEUTICS, INC. | Directeur Général | 02/02/2024 |
SAB Sciences, Inc.
 SAB Sciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical development company | Président | - |
Anciens postes connus de Samuel Reich
| Sociétés | Poste | Fin |
|---|---|---|
| BIG CYPR | Directeur Général | 22/10/2021 |
Biscayne Neurotherapeutics, Inc.
 Biscayne Neurotherapeutics, Inc. BiotechnologyHealth Technology Develops novel treatments for epilepsy, pain and other central nervous system disorders | Fondateur | 01/10/2018 |
Biscayne Pharmaceuticals, Inc.
 Biscayne Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs and pharmaceutical products | Fondateur | 01/10/2018 |
| OPKO HEALTH, INC. | Corporate Officer/Principal | 01/11/2008 |
eXegenics, Inc.
 eXegenics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | 13/06/2007 |
Formation de Samuel Reich
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
29
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
eXegenics, Inc.
eXegenics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Acuity Pharmaceuticals, Inc.
 Acuity Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Developed pharmaceutical products | Commercial Services |
Biscayne Pharmaceuticals, Inc.
Biscayne Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs and pharmaceutical products | Health Technology |
Clark University
 Clark University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OPKO Health, Inc.
 OPKO Health, Inc. Medical/Nursing ServicesHealth Services Engages in biopharmaceutical and diagnostics | Health Services |
Biscayne Neurotherapeutics, Inc.
Biscayne Neurotherapeutics, Inc. BiotechnologyHealth Technology Develops novel treatments for epilepsy, pain and other central nervous system disorders | Health Technology |
SAB Sciences, Inc.
SAB Sciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical development company | Health Technology |
Big Cypress Acquisition Corp.
 Big Cypress Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
SAB Biotherapeutics, Inc.
 SAB Biotherapeutics, Inc. BiotechnologyHealth Technology Engages in advancing a new class of immunotherapies | Health Technology |
